Ortal Buhbut

Dr. Ortal Buhbut


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2023 in International Ophthalmology
Verified
Journal Article
Closed access
PDF file
OBOrtal Buhbut
Ortal Buhbut
AAAsaf Achiron
Asaf Achiron
BKBoris Knyazer
Boris Knyazer
SKShiri Kantor
Shiri Kantor
CSCarmel Shinar
Carmel Shinar
HAHaggay Avizemer
Haggay Avizemer

15 November 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
OBOrtal Buhbut
Ortal Buhbut
HAHadas Ben Assayag
Hadas Ben Assayag
SBSapir Aharoni- Bar
Sapir Aharoni- Bar
MEMaor Epstein
Maor Epstein
ETErez Tsumi
Erez Tsumi
Anat HorevAnat Horev
Anat Horev
Objective: Patients with chronic idiopathic intracranial hypertension (IIH) commonly experience a high level of disability and low satisfaction with medical treatment. We aim to evaluate long-term functional improvement and patient satisfaction in IIH patients with similar symptoms by comparing venous sinus stenting (VSS) to standard medical therapy. Methods: We conducted a cross-sectional questionnaire study of 111 IIH patients, comparing 37 adult female patients who underwent venous sinus stenting with 74 patients treated medically. Propensity score matching was used to balance age and presence of papilledema at presentation between groups. Headache-related disability was evaluated using the Migraine Disability Assessment Scale (MIDAS), while general function and treatment satisfaction were assessed using custom questionnaires. Electronic medical records and the results of imaging upon diagnosis were reviewed retrospectively. Results: The stented group reported significantly better outcomes in physical well-being (median 4.0 vs. 1.0, p < 0.001), task completion (4.0 vs. 1.0, p < 0.001), work/school persistence (5.0 vs. 1.0, p < 0.001), and mental well-being (4.0 vs. 1.0, p < 0.001). Additionally, the stented group had a lower proportion of patients with severe MIDAS (MIDAS > 4, 24.3% vs. 47.9%, p = 0.017). Logistic regression suggested venous stenting as a protective factor against severe MIDAS scores (OR = 0.174, p = 0.004). Conclusion: Cerebral venous stenting in patients with IIH is associated with lower disability and higher patient satisfaction from medical treatment compared to those treated with medications only. These findings suggest that venous sinus stenting may be a valuable treatment option for selected IIH patients. However, larger prospective studies are needed to further validate our results.

21 April 2026 in Journal of Glaucoma
Verified
Journal Article
Closed access
AIAhed Imtirat
Ahed Imtirat
MHManal Abu Rabia- Huleihel
Manal Abu Rabia- Huleihel
OBOrtal Buhbut
Ortal Buhbut
YKYoav Kalron
Yoav Kalron
ETErez Tsumi
Erez Tsumi
AKAssaf Kratz
Assaf Kratz
Précis: PreserFlo™ MicroShunt implantation significantly reduced intraocular pressure and medication burden in refractory childhood glaucoma. However, declining survival beyond 12 months indicates limited long-term durability. Purpose: Childhood glaucoma is a potentially blinding condition caused by elevated IOP, with particularly high prevalence in Southern Israel. Management is especially challenging in refractory cases. The Preserflo™ MicroShunt is a minimally invasive device designed to lower IOP by diverting aqueous humor to the subconjunctival space. This study presents our institutional experience with its use in refractory childhood glaucoma and, to our knowledge, represents the largest reported series to date. Methods: We conducted a retrospective study of all consecutive children (≤18 y) with refractory glaucoma defined as inadequate IOP control despite prior glaucoma surgery and maximal medical therapy, who underwent PMS implantation between October 2023 and December 2024. Data collected included pre- and postoperative IOP and number of IOP-lowering medications. Complete success was defined as IOP <21 mmHg and ≥25% IOP reduction without medications; Qualified success allowed for medications. Failure was defined as <25% IOP reduction or need for further surgery. Results: Thirty-four eyes from 27 patients (mean age 4.9 ± 3.6 y) were included. Mean follow-up was 14.85 ± 5.02 months. Mean IOP decreased from 24.29±6.05 mmHg to 17.95 ± 8.22 mmHg ( P < 0.001), and mean medication numbers from 3.0 ± 0.0 to 0.9 ± 1.3 ( P < 0.001). Overall success was 61.70%, 50% achieving complete success with an average follow-up time of 13.92±4.85 months. Conclusion: The PMS lowered IOP and reduced medication use in refractory childhood glaucoma. However, the declining survival rates (53% at 12 mo and 33% at 24 mo) indicate the need for further evaluation of its long-term efficacy in children.